A pen to pin down the fringes of cancer

Mass spectrometry is a powerful tool for analysing the molecular composition in a tissue sample, which is invaluable information during cancer surgery. However, mass spectrometers are complex and unwieldy – certainly a poor fit for a live OR setting. To build a bridge between the lab and the OR, Professor Livia S Eberlin from Baylor College of Medicine devised a very special pen.

Report: Wolfgang Behrends

Photo
Dr. James Suliburk, head of endocrine surgery at Baylor College of Medicine, using the MasSpec Pen during a thyroid surgery.
Source: Dr. James Suliburk, Baylor College of Medicine

Surgical removal of cancerous tissue is a formidable tightrope walk: cut out too little, and the tumour might return; cut out too much, and damage to the surrounding tissue becomes an issue – especially in vital organs. But where to draw the line when the border between cancer and healthy tissue is invisible to the naked eye? This is where mass spectrometry comes in since “Mass spec is an amazing tool to quickly measure and analyse molecules in a sample,” Professor Eberlin explains. She adds that “The molecular makeup is highly reflective of our biological system – when we become diseased, its composition will change in a characteristic way, which can then be detected via mass spectrometry.”

To put it simply, when applied to a tissue sample, mass spectrometry can tell the difference between cancerous and non-cancerous cells. However, due to its complexity, the technology has largely been used in research and development laboratories, but has seen limited use in hospitals and operating rooms. The new tool developed by Prof. Eberlin’s team, called the MasSpec Pen, aims to change this: “We envisioned and designed the MasSpec Pen to be an easy-to-use, handheld interface between the surgeon and the mass spectrometer.”

How it works

During surgery, the device is held against the tissue in question. “The tip of the pen holds a droplet of water which acts as a solvent to extract molecules from a sample. After 3 to 5 seconds of direct contact with the tissue, a vacuum transports the droplet to the mass spectrometer, where the molecules in the droplet are read.” 

Using machine learning technology, the device has been trained to identify molecular patterns of different cancers, such as breast, ovarian, pancreatic or thyroid cancer. The system is able to translate this complex information into easy-to-read visual or auditory cues, says Prof. Eberlin: “This might be a low pitch signal for healthy tissue, and high pitch for cancer, so that the surgeon could act upon this feedback immediately, while remaining focused on the patient.” To ensure hygiene and prevent infections, the contact areas of the pen are disposable but can also be sterilised with an autoclave for re-use.

Jialing Zhang demonstrates using the MasSpec Pen on a human tissue sample.
Jialing Zhang demonstrates using the MasSpec Pen on a human tissue sample.
Source: Vivian Abagiu/Univ. of Texas at Austin

While the information gathered from the molecular readout is not quite as specific as, for example, a genetic analysis, the expression of the molecules offers a very robust disease indication with accuracies ranging from 92 to 99 percent, depending on the cancer type. “Still, we need to be aware of potential error, be it from mixed tissue composition in dispersed cancers or other tissue features like necrosis, which can potentially skew the analysis. But overall, the powerful insight gained is clearly worth it.”

One of the main appeals of the device is its quick result delivery. This is a huge upgrade compared to the current standard, which is frozen section analysis of the tissue. “When the sample needs to be taken out, sent to a pathologist and analysed, it takes a lot of time. Also, the freezing process can alter the sample tissue, which may affect diagnostic accuracy. The MasSpec Pen keeps the process within the OR and provides results within 15 seconds in vivo or from the freshly excised tissue. This circumvents the need to move and freeze the tissue.”

Potential for further applications

The pen is currently being validated for patients in clinical studies at Baylor College of Medicine and MD Anderson Cancer Center, both in Houston, Texas. According to Prof. Eberlin, the device can essentially be used in any type of solid tumour, which opens up many additional applications, such as prostate or brain cancer. Additionally, the developers are exploring the potential of the pen in forensic settings, for example to detect illicit drugs on surfaces or pesticides in fruit. “We even used it to determine certain kinds of meat and fish, which might be mislabelled as higher-quality products to achieve a higher price on the market,” Professor Eberlin explains. 

However, to avoid taking on too many aspects at a time, current clinical studies focus on the pen’s application in breast, pancreas and ovarian cancers. “We are taking this one step at a time,” says Prof. Eberlin. “Right now, we are probably 3 to 5 years from deployment in hospitals.” Besides fine-tuning the technology, a lot of this time will be taken up by regulatory steps, such as submitting the design to the U.S. Food and Drug Administration (FDA) for approval as a medical device. Prof. Eberlin is confident that the MasSpec Pen has the potential to be a great asset to surgeons in removing all cancer cells and thus improve patient outcomes.

Portrait Livia Schiavinato Eberlin
Livia Schiavinato Eberlin

Profile:
Livia Schiavinato Eberlin is Associate Professor in the Department of Surgery at Baylor College of Medicine and Adjunct Professor in the Chemistry Department at the University of Texas at Austin. Her research group is focused on developing mass spectrometry technologies to address critical problems in health-related research. Her passion for mass spectrometry started as an undergraduate research assistant at the State University of Campinas (UNICAMP) in Brazil. 

During her PhD studies, she developed and applied ambient ionization MS imaging to human cancer diagnosis. In recognition of her innovative work, Prof. Eberlin and her research team have received many awards including the Nobel Laureate Signature Award from the American Chemical Society, the L’Oréal for Women in Science Fellowship, a Moore Inventor Award and a MacArthur Fellowship.


You are a professional from the emtech ecosystem and interested in sharing your tech tale with a guest contribution at Tectales? Just contact us: editorial@tectales.com.

Subscribe to our newsletter

Related articles

MasSpec Pen shows promise in pancreatic cancer surgery

MasSpec Pen shows promise in pancreatic cancer surgery

The MasSpec Pen has shown to accurately identify tissues and surgical margins directly in patients and differentiate healthy and cancerous tissue from banked pancreas samples.

AI finds patterns of mutations in tumour images

AI finds patterns of mutations in tumour images

Researchers have developed an AI algorithm that uses computer vision to analyze tissue samples from cancer patients.

Machine learning helps diagnose leukemia

Machine learning helps diagnose leukemia

Researchers at the University of Bonn show how artificial intelligence improves the evaluation of blood analysis data.

AI method can detect precursors to cervical cancer

AI method can detect precursors to cervical cancer

Using AI and mobile digital microscopy, researchers hope to create screening tools that can detect precursors to cervical cancer in women in resource-limited settings.

AI system for the diagnosis of breast cancer

AI system for the diagnosis of breast cancer

Researchers have developed a new tissue-section analysis system for diagnosing breast cancer based on artificial intelligence.

Mouth and throat cancer: Robotic surgery may improve outcomes

Mouth and throat cancer: Robotic surgery may improve outcomes

Robotic surgery for patients with early stage, oropharyngeal squamous cell cancer is associated with improved health outcomes, including better long-term survival.

ConvPath software uses AI to identify cancer cells

ConvPath software uses AI to identify cancer cells

A software tool uses artificial intelligence to recognize cancer cells from digital pathology images — giving clinicians a powerful way of predicting patient outcomes.

Deep learning identifies molecular patterns of cancer

Deep learning identifies molecular patterns of cancer

An AI platform can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process.

Using AI to predict risk of thyroid cancer on ultrasound

Using AI to predict risk of thyroid cancer on ultrasound

Researchers from Thomas Jefferson University use machine learning on ultrasound images of thyroid nodules to predict risk of malignancy.

Popular articles

Subscribe to Newsletter